
AxoGen (AXGN) Stock Forecast & Price Target
AxoGen (AXGN) Analyst Ratings
Bulls say
Axogen is a promising company with a strong revenue growth, higher gross margin, and increasing profitability. With potential expansion in new segments and positive financials, the company has a positive outlook for the future. However, the company may face risks such as market penetration and commoditization. Overall, AXGN has a solid product portfolio and a presence in the prostate market, with potential for further growth and expansion after the completion of their clinical trials.
Bears say
Axogen is a company that has a strong focus on the extremities market and its portfolio of nerve repair products. However, the company's financials, including its EV/EBITDA and P/E ratios, show that it is currently overvalued compared to its peers. While the company has potential for growth with its products and partnerships, it still faces challenges in terms of market development and clinical efforts, and the lack of reimbursement for its nerve repair devices. Additionally, there is a lack of evidence in the Urology market, where the company is trying to expand, and the executive compensation structure raises potential concerns about alignment with shareholder interests. Overall, these factors contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.
AxoGen (AXGN) Analyst Forecast & Price Prediction
Start investing in AxoGen (AXGN)
Order type
Buy in
Order amount
Est. shares
0 shares